ADMA
ADMA Biologics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow -3.6% ·
net new positions -6.2%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | -1 | 146.16M | $1.22B | +9 | −12 |
| Q1 2026 | 111 | -5 | 163.83M | $1.48B | +7 | −12 |
| Q4 2025 | 115 | +1 | 163.64M | $2.98B | +1 | n/a |
| Q3 2025 | 19 | +1 | 92.34M | $1.35B | +3 | −3 |
| Q2 2025 | 16 | -1 | 89.41M | $1.63B | +1 | −2 |
| Q1 2025 | 14 | 0 | 31.71M | $629.12M | n/a | n/a |
| Q4 2024 | 14 | +2 | 37.00M | $634.64M | +2 | n/a |
| Q3 2024 | 11 | -2 | 23.86M | $476.89M | n/a | −2 |
| Q2 2024 | 13 | n/a | 23.97M | $268.00M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 36.47M | n/a | $664.18M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 2 | The Vanguard Group ✦ (passive) | 21.36M | n/a | $389.03M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 12.08M | +5.6% | $219.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 5.91M | +4.3% | $107.69M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Fidelity (FMR) ✦ | 3.21M | n/a | $58.50M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 6 | Renaissance Technologies ✦ | 3.15M | -11.3% | $57.29M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 2.14M | +1.3% | $38.96M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 1.20M | -46.7% | $21.89M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Millennium Management ✦ | 1.14M | -47.1% | $20.68M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Wellington Management ✦ | 931.94K | +893.3% | $16.97M | 0.0% | ▲ Add | 5 | SEC ↗ ×7 |
| 11 | D. E. Shaw & Co. ✦ | 832.56K | -45.4% | $15.16M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 459.88K | -11.5% | $8.37M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 13 | Arrowstreet Capital ✦ | 360.56K | -67.7% | $6.57M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 108.99K | -33.6% | $1.98M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Norges Bank ✦ (passive) | 30.13K | 0.0% | $548,722 | 0.0% | Held | 3 | SEC ↗ |
| 16 | Marshall Wace ✦ | 21.09K | New | $384,048 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $384,048 | 0.0% |
Exited
| Point72 Asset Management | $16.82M | was 0.0% |
| Citadel Advisors | $4.79M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 355 holders, 211.31M shares, $1.84B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.